BMS-986458

Overview

BMS-986458 is a highly selective, orally active cereblon-based BCL6 PROTAC degrader and antitumor agent. BMS-986458 selectively degrades BCL6 by binding cereblon to the BTB domain of BCL6 , thereby regulating the cell cycle, antiproliferative and interferon signaling pathways, and upregulating the expression and distribution of CD20 . BMS-986458 modulates the phenotype of follicular helper T cells and reduces circulating tumor DNA levels. The combination of BMS-986458 with CD20xCD3 bispecific antibody also enhances the efficiency of T cell tumor infiltration and expansion. BMS-986458 induces regression of BCL6-positive tumors and prolongs survival, and it is suitable for research related to B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and relapsed/refractory lymphoma. (Pink: BCL6 ligand ( HY-172740 ); Blue: Cereblon ligand ( HY-W593794 ); Black: linker ( HY-W267161 )).

Application

Products | Products > Disease Areas > Blood Disease | Products > Disease Areas > Non-Hodgkin Lymphoma | Products > Disease Areas > Diffuse Large B-cell Lymphoma | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > BCL6 | Products > Signaling Pathways > CD20

Product Information

• Catalog No.: HY-172736
• CAS No.: 3005272-36-3
• Molecular Formula: C32H34ClN9O3
• Molecular Weight: 628.12
• Purity: 99.65%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (3.98 mM); Clear solution
• Availability: In-stock

Source

Original product source